Recent and current Phase II clinical trials in endometrial cancer: review of the state of art. (Q38203354)

30 August 2017

title

Recent and current Phase II clinical trials in endometrial cancer: review of the state of art. (English)

1 reference

30 August 2017

main subject

phase II clinical trial

0 references

1 reference

Stephanie Lheureux

1 reference

30 August 2017

Michelle Wilson

series ordinal

1 reference

30 August 2017

Helen J Mackay

series ordinal

1 reference

30 August 2017

language of work or name

English

0 references

publication date

9 April 2014

1 reference

Expert Opinion on Investigational Drugs

30 August 2017

published in

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

773-792

1 reference

30 August 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Endometrial cancer and a family history of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Type I and II endometrial cancers: have they different risk factors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Hereditary gynaecological malignancies: advances in screening and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

mTOR signaling and drug development in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

PTEN1 is frequently mutated in primary endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Adjuvant therapy for early-stage endometrial cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

A phase II evaluation of docetaxel and carboplatin followed by tumor volume directed pelvic plus or minus paraaortic irradiation for stage III endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Conservative treatment of early endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Intrauterine progesterone treatment of early endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Emerging therapeutic targets in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Recent advances in systemic therapy for advanced endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Contemporary management of endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Hormone therapy in advanced and recurrent endometrial cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Molecular profiling of endometrial malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Understanding the benefit of metformin use in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Use of metformin and the risk of ovarian cancer: a case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Metformin use is associated with better survival of diabetic patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Diabetes, metformin, and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Metformin use and endometrial cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Metformin is associated with improved survival in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Obesity and hormone therapy in breast cancer: an unfinished puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Evaluation of treatment benefit: randomized controlled trials and population-based observational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.907272

10.1517/13543784.2014.907272

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference